Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 495
- Registration Number
- NCT01689519
- Locations
- 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇬🇧Velindre Cancer Centre, Cardiff, United Kingdom
🇦🇺Lismore Base Hospital; Cancer Care & Haematology Unit, Lismore, New South Wales, Australia
A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Neoplasms
- Interventions
- Biological: Atezolizumab [TECENTRIQ]Biological: Vanucizumab
- First Posted Date
- 2012-09-19
- Last Posted Date
- 2018-10-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 132
- Registration Number
- NCT01688206
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇧🇪Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇫🇷Centre Francois Baclesse; Oncologie, Caen, France
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT01684891
An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 22
- Registration Number
- NCT01684865
- Locations
- 🇲🇰
University Clinic of Hematology Skopje, Hospital Care Department, Skopje, Macedonia, The Former Yugoslav Republic of
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 208
- Registration Number
- NCT01684878
- Locations
- 🇳🇱
Academ Ziekenhuis Groningen; Medical Oncology, Groningen, Netherlands
🇳🇱Academisch Ziekenhuis Leiden; Clinical Oncology, Leiden, Netherlands
🇳🇱UMC St Radboud, Nijmegen, Netherlands
Observational Study of Tocilizumab in Participants With Rheumatoid Arthritis in Australia
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: Observational study
- First Posted Date
- 2012-09-12
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 37
- Registration Number
- NCT01683604
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
- Conditions
- Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
- Interventions
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT01680991
A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01680978
A Study to Investigate the Effects of Rifampicin on the Pharmacokinetics of Aleglitazar in Healthy Volunteers
- First Posted Date
- 2012-09-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT01679639
An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2012-09-06
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 7500
- Registration Number
- NCT01679834